Comparing P53 expression and genome-wide transcriptome profiling to Comet assay in lymphocytes from melanoma patients and healthy controls.
Journal
Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288
Informations de publication
Date de publication:
01 11 2023
01 11 2023
Historique:
received:
01
02
2023
accepted:
13
10
2023
medline:
3
11
2023
pubmed:
2
11
2023
entrez:
2
11
2023
Statut:
epublish
Résumé
This study compared the expression of TP53 in lymphocytes from malignant melanoma (MM) patients with positive sentinel nodes to healthy controls (HCs) following exposure to various doses of UVA radiation. The Lymphocyte Genome Sensitivity (LGS) assay indicated significant differences in DNA damage in lymphocytes between MM patients and HCs. qPCR data demonstrated an overall 3.4-fold increase in TP53 expression in lymphocytes from MM patients compared to healthy controls, following treatment with 0.5 mW/cm
Identifiants
pubmed: 37914759
doi: 10.1038/s41598-023-44965-z
pii: 10.1038/s41598-023-44965-z
pmc: PMC10620420
doi:
Substances chimiques
Tumor Suppressor Protein p53
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
18858Informations de copyright
© 2023. The Author(s).
Références
Mol Cell Biol. 2003 Dec;23(23):8576-85
pubmed: 14612402
Mol Cytogenet. 2014 Jan 21;7(Suppl 1 Proceedings of the International Conference on Human):I7
pubmed: 24955127
Br J Dermatol. 2014 Aug;171(2):234-41
pubmed: 24665835
Immunity. 2000 Feb;12(2):121-7
pubmed: 10714678
FEBS Lett. 2019 Nov;593(22):3101-3119
pubmed: 31663111
Arch Surg. 1992 Apr;127(4):392-9
pubmed: 1558490
Environ Mol Mutagen. 2018 Jun;59(5):438-460
pubmed: 29466611
F1000Res. 2019 Nov 7;8:1874
pubmed: 33552473
Cancers (Basel). 2018 May 23;10(6):
pubmed: 29789497
FASEB Bioadv. 2018 Dec 20;1(1):32-39
pubmed: 32123810
Sci Rep. 2020 Jun 3;10(1):9070
pubmed: 32493953
Nat Rev Cancer. 2014 May;14(5):359-70
pubmed: 24739573
Bioinformatics. 2015 Jan 15;31(2):166-9
pubmed: 25260700
Cancer Immunol Res. 2015 Aug;3(8):827-35
pubmed: 26242760
Cell Death Differ. 2018 Jan;25(1):93-103
pubmed: 29099489
J Oncol. 2022 Nov 4;2022:9359879
pubmed: 36385955
Hum Mutat. 2007 Jun;28(6):578-88
pubmed: 17295241
J Mol Biol. 2021 May 28;433(11):166913
pubmed: 33676929
Dermatopathology (Basel). 2018 Feb 9;5(1):21-25
pubmed: 29719827
J Pharm Pharmacol. 2008 Aug;60(8):969-76
pubmed: 18644190
Curr Protoc Bioinformatics. 2016 Jun 20;54:1.30.1-1.30.33
pubmed: 27322403
Lancet Oncol. 2009 Aug;10(8):751-2
pubmed: 19655431
Cell Metab. 2017 Jun 6;25(6):1254-1268.e7
pubmed: 28591633
Nucleic Acids Res. 2018 Jul 2;46(W1):W537-W544
pubmed: 29790989
Oncotarget. 2018 May 4;9(34):23780-23823
pubmed: 29805774
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Lancet. 2018 Sep 15;392(10151):971-984
pubmed: 30238891
Cell Rep. 2015 Sep 8;12(10):1564-74
pubmed: 26321644
Am J Pathol. 2009 Jun;174(6):2367-77
pubmed: 19389934
Mutagenesis. 2012 May;27(3):351-7
pubmed: 22155984
Cancer Res. 2004 Nov 15;64(22):8199-207
pubmed: 15548685
Int J Cancer. 2017 Apr 15;140(8):1907-1917
pubmed: 27935036
Oncotarget. 2015 Sep 29;6(29):28173-82
pubmed: 26334217
Front Cell Dev Biol. 2021 Feb 18;9:648808
pubmed: 33681231
Free Radic Biol Med. 2008 Apr 15;44(8):1529-35
pubmed: 18275858
Cancer Res. 2003 Apr 1;63(7):1464-9
pubmed: 12670891
Eur J Cancer. 2006 Apr;42(6):760-7
pubmed: 16510278
Nucleic Acids Res. 2020 Jan 8;48(D1):D498-D503
pubmed: 31691815
BMC Genomics. 2011 Oct 14;12:507
pubmed: 21999641
Bioinformatics. 2013 Jan 1;29(1):15-21
pubmed: 23104886
Oncogene. 1993 Jan;8(1):203-7
pubmed: 8093810
Front Plant Sci. 2022 Jun 02;13:904392
pubmed: 35720556
FASEB J. 2014 Oct;28(10):4563-70
pubmed: 25063845
Oxid Med Cell Longev. 2018 Aug 2;2018:1454936
pubmed: 30174780
Signal Transduct Target Ther. 2021 Jul 12;6(1):263
pubmed: 34248142
Nat Rev Cancer. 2002 Aug;2(8):594-604
pubmed: 12154352
Oncotarget. 2014 Apr 15;5(7):1701-52
pubmed: 24743024